Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 15Uterine Cervical Neoplasms 13Fallopian Tube Neoplasms 4Recurrence 3Melanoma 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Sarcoma 2Prostatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Carcinoma 2Breast Neoplasms 2Advanced Endometrial Cancer 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Endometrial Stromal 1Platinum-resistant Recurrent Ovarian Cancer 1Pelvic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasm Metastasis 1

Interventions

Bevacizumab 21-dodecylpyridoxal 2tremelimumab 1durvalumab 1Paclitaxel 1Injections 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Platinum-resistant Recurrent Ovarian Cancer × Injections × Gynecologic × Clear all
NCT05325229 2022-10-13

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
94 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡